Puma Biotechnology | PBYI - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Exelixis USD 359.47M 3.28M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 5.62B 4.5B 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Moderna USD 1.78B 242M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Takeda JPY 1.11T 85.29B 2026-03
TG Therapeutics USD 170.12M 28.04M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03